

October 21, 2023

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Pursuant to Regulation 30, read with Clause 20 Para A of Part A of Schedule III, of SEBI Listing Regulations, we hereby inform you that one of our subsidiary has received an order on October 20, 2023 from the Sales Licencing & Enforcement Authority, Medchal, Malkajgiri District, Telangana, a suspension of drug license order dated October 19, 2023 for one of pharmacy outlet.

The detailed disclosure with respect to the order as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 is enclosed herewith as “Annexure I”

The aforesaid information is also being placed on the website of the Company at www.medplusindia.com

Kindly take the same on your records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS 7460

Annexure A

Details required under the Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

Particulars	Description
Name(s) of the Authority	Sales Licensing & Enforcement Authority, Medchal, Malkajgiri District, Telangana
Nature and details of the action(s) taken, initiated or order(s) passed	Suspension of drug license for 7 days from the date of receipt of order for one of Pharmacy outlet.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Received order on October 20, 2023
Details of the violation(s)/ contravention(s) committed or alleged to be committed	Violation of Rule 65(2) and 65(9)(a) under Drugs and Cosmetics Act, 1940 and Rules, 1945
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Loss of sales for seven days. However, this has no material impact on the operation of the Company